StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Equities research analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Down 33.3 %

Shares of ADXS opened at $0.03 on Thursday. The stock has a market cap of $1.28 million, a PE ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.78. The stock has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.04.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.